Table 2.
Clinical profile of patients according to type of medication used
| Treatment | Gender (male) | Age (years) | FEV1 (post-BD, % predicted) | FVC (post-BD, % predicted) | FEV1/FVC (%) | mMRC grade | CAT score | BODEx index | Daytime symptom score | Early morning symptom score | Night-time symptom score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No treatment | 12 (52.2) | 67.8±9.6 | 51.9±17.8 | 70.6±19.5 | 54.0±10.6 | 1.4±1.0 | 13.7±10.1 | 2.4±1.9 | 8.8±6.3 | 2.5±2.5 | 2.4±3.3 |
| SABA or SAMA (only) | 43 (68.3) | 69.5±9.4 | 50.7±17.8 | 69.7±19.5 | 53.3±11.8 | 1.6±1.0 | 15.1±7.8 | 2.9±1.6 | 10.7±6.9 | 3.7±4.0 | 3.1±4.7 |
| LABA | 29 (56.9) | 69.2±8.1 | 51.3±16.6 | 74.3±16.5 | 50.3±11.0 | 1.6±1.1 | 156.8±9.6 | 2.5±1.8 | 10.2±8.1 | 3.5±4.1 | 3.1±4.4 |
| LAMA | 26 (56.5) | 70.3±8.1 | 55.9±19.9 | 81.8±20.9 | 49.6±10.8 | 1.7±1.0 | 11.9±7.2 | 2.3±2.0 | 7.1±5.6 | 2.2±2.6 | 1.5±2.6 |
| LABA/LAMA | 53 (58.9) | 69.2±9.0 | 48.9±15.7 | 75.4±17.1 | 47.6±10.9 | 1.8±0.9 | 15.1±7.9 | 2.7±1.7 | 10.0±7.1 | 2.6±2.9 | 1.5±2.3 |
| ICS | 22 (64.7) | 69.6±9.4 | 53.4±19.3 | 72.3±19.8 | 53.7±10.0 | 1.8±1.2 | 15.6±7.0 | 2.8±2.0 | 9.5±6.0 | 3.3±2.5 | 2.6±3.3 |
| ICS/LABA | 124 (56.4) | 69.2±8.9 | 52.4±17.2 | 74.7±18.0 | 51.2±10.7 | 1.8±1.1 | 15.5±8.7 | 2.7±1.9 | 10.5±7.5 | 3.6±3.7 | 2.4±3.6 |
| ICS/LAMA/LABA | 161 (61.5) | 69.8±8.5 | 44.7±16.8 | 71.0±19.3 | 46.0±11.5 | 2.0±1.0 | 15.7±7.6 | 3.3±1.8 | 10.2±6.6 | 3.2±3.7 | 2.2±3.7 |
| Other | 4 (66.7) | 70.5±8.2 | 45.0±25.2 | 61.4±29.6 | 52.7±11.2 | 1.3±0.8 | 14.0±7.5 | 2.4±1.8 | 5.3±4.0 | 3.0±3.3 | 1.7±2.3 |
Notes: Data are shown as n (%) or mean ± SD. LAMA, LABA/LAMA, ICS, ICS/LABA, ICS/LAMA/LABA, ICS/LAMA could be used alone or in combination with SABA or SAMA.
Abbreviations: BMI, body mass index; BD, bronchodilator; mMRC, modified Medical Research Council Dyspnea Scale; CAT, COPD Assessment Test; BODEx, BMI, Obstruction, Dyspnea, and Exacerbations; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.